BLFS vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BLFS exhibits a weak fundamental health profile with a Piotroski F-Score of 2/9, indicating significant financial distress risks, and lacks an Altman Z-Score for further validation. Despite strong revenue growth of 31.2% and improving earnings surprises in recent quarters, profitability remains negative with negative ROE and ROA. The stock trades at a high valuation with a Forward P/E of 155.44 and Price/Sales of 11.96, above sector averages, while insider selling activity raises caution. Analysts maintain a strong_buy consensus, but this is not yet supported by robust cash flow or consistent earnings generation.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BLFS vs LLY: Head-to-Head Comparison
This page compares BioLife Solutions, Inc. (BLFS) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.